TrimRx vs Henry Meds vs PlexusDx compared on real annual cost, pricing transparency, reviews, BBB, FDA status, and genetic-guided dosing. TrimRx $199/mo standard async; Henry Meds $297/mo standard with video visit; PlexusDx from $129/mo with optional Precision Peptide Genetic Test ($99 add-on).

The best tirzepatide online in 2026 depends on insurance status, format, and whether you want a genetic baseline guiding titration. Compare MEDVi, YUCCA Health, Willow, Eden, and TrimRX against PlexusDx Tirzepatide Injection ($229–$309/mo) and Tirzepatide Oral ($229–$509/mo), with the optional Precision Peptide Genetic Test for personalized dosing.

TrimRx vs Ro vs PlexusDx in 2026: real annual cost math, compounded vs FDA-approved branded medication, oral pill options, safety oversight, and the genetic-baseline option that only PlexusDx offers. Includes a four-question decision frame and pricing across PlexusDx Microdose GLP-1, Semaglutide Injection, Tirzepatide Injection, and GLP-Squared.

SkinnyRx vs MEDVi vs PlexusDx compared on cost, formats, oversight, FDA warning letters, and genetic personalization — with PlexusDx Microdose at $129/mo flat as the cheapest cash-pay tier and the Precision Peptide Genetic Test as the only genetic baseline in the three-way comparison.

SHED vs Ro vs PlexusDx for cash-pay GLP-1 weight loss in 2026 — compounded vs FDA-approved branded, real annual cost math, insurance posture, format flexibility, and why genetics inform PlexusDx dose decisions before week one.

Rybelsus (oral semaglutide) is FDA-approved for type 2 diabetes only — not for weight loss. See the real PIONEER weight numbers, the ~$998/month cash price, why insurance rarely covers off-label use, and how PlexusDx Semaglutide Oral ($209/mo+) and the Microdose GLP-1 Protocol ($129/mo) compare on cost and dose flexibility.

Retatrutide (Lilly's investigational triple agonist) and orforglipron (Lilly's oral non-peptide GLP-1) are the two big pipeline stories in 2026 — but neither is FDA-approved yet. Here's the realistic timeline, the Phase 3 data, the announced and unknown pricing, and how PlexusDx's currently-available compounded semaglutide and tirzepatide protocols ($129–$509/mo) compare for someone who needs an option today rather than in 2028.

Oral semaglutide vs injectable semaglutide in 2026: Rybelsus, the new Wegovy pill, Ozempic, and Wegovy injection compared on dose, bioavailability, effectiveness, and cost — plus where PlexusDx Semaglutide Oral ($209/mo+), Semaglutide Injection ($179–$229/mo), and Microdose GLP-1 Protocol ($129/mo flat) fit as cash-pay alternatives covering both pill and shot formats.

MEDVi vs TrimRx vs PlexusDx in 2026: real cash-pay GLP-1 pricing, compounded vs branded, multi-month upfront vs month-to-month, and where genetic testing changes the dose conversation before week one.

MEDVi vs Ro vs PlexusDx for cash-pay GLP-1 weight loss: real annualized cost math, compounded vs FDA-approved branded, safety considerations, and where genetic baselining changes the dose decision before week one.

MEDVi, Remedy Meds, and PlexusDx all dispense compounded semaglutide and tirzepatide — but the annualized cost, billing cadence, and clinical-oversight model differ in ways the landing pages don't show. This guide walks the real numbers, the September 2025 FDA warning-letter context, and where PlexusDx Weight Management Protocols ($129–$325/mo) plus the Precision Peptide Genetic Test fit relative to both.

MEDVi vs Lilly Direct vs PlexusDx in 2026: all-inclusive compounded telehealth, FDA-approved Zepbound at self-pay vial pricing, and a genetics-anchored compounded protocol. Real 12-month math, the 45-day refill trap, and where each fits.

MEDVi vs Hims vs PlexusDx in 2026: MEDVi at $179 first month then $299/mo with no contract, Hims at $199/mo gated behind a $1,194 six-month prepayment, and PlexusDx Weight Management Protocols from $129/mo with no upfront commitment and an optional Precision Peptide Genetic Test for genetic-guided GLP-1 dosing.

MEDVi vs Hers vs PlexusDx in 2026: real annual cost math, compounded vs FDA-approved branded medication source, tirzepatide availability across all three, cancellation and refund policy differences, and where the Precision Peptide Genetic Test fits when GLP-1 response varies by GLP1R, GIPR, FTO, MC4R, and TCF7L2 variants.

MEDVi vs Gala GLP-1 vs PlexusDx compared on verified 2026 pricing, compounded vs FDA-approved status, cancellation rules, and where a genetic baseline changes the dose decision before week one.

Eight GLP-1 programs publish verified outcome-based money-back guarantees as of April 2026 — Eden, SHED, Brightmeds, Fella Health, RemedyMeds, Calibrate, Aayu Well, and LifeMD — each with 6–12 month windows and structured adherence requirements. PlexusDx does not offer an outcome guarantee but prices flat with no membership and no required commitment, so risk is bounded by one month of cost rather than by a 6–12 month adherence schedule.

Eden vs Ro vs PlexusDx for cash-pay GLP-1 weight loss in 2026: real annualized cost math on Eden’s $129–$329/mo all-inclusive compounded plans, Ro’s $149/mo membership plus FDA-approved branded medication (Wegovy, Zepbound, Ozempic, Foundayo), and PlexusDx Weight Management Protocols from $129/mo — with the Precision Peptide Genetic Test as a $99 add-on so dosing is anchored to GLP1R, GIPR, FTO, MC4R, and TCF7L2 variants before week one.

Compare the best online tirzepatide providers in 2026 — Ro, Eden, Yucca Health, Willow, Sesame — against the PlexusDx Tirzepatide Injection ($229–$309/mo) and Tirzepatide Oral ($229–$509/mo) Protocols, with a genetic baseline option no other provider offers.

How PlexusDx Weight Management Protocols compare to the major cash-pay GLP-1 programs in 2026 — Mochi, Eden, MEDVi, Ro, GoodRx Care Direct, NovoCare, and LillyDirect — on price, medication source, membership fees, and total annualized cost.

Compounded tirzepatide provider rankings cycle through MEDVi, Eden, Yucca Health, Willow, and Trim RX. PlexusDx Tirzepatide Injection ($229–$309/mo) and Tirzepatide Oral ($229–$509/mo) compare on price, oversight, and genetic-test personalization.

A buyer-side read of the seven brand-name GLP-1 telehealth providers (Ro, Walgreens, GoodRx, Hims & Hers, PlushCare, Sesame, WeightWatchers) covering true month-one cost, what each dispenses, and how PlexusDx compounded protocols ($129–$325/mo, all-inclusive, no membership) fit when branded coverage isn't accessible.

Semaglutide and Tirzepatide are widely compared GLP-1 pathway compounds. This head-to-head covers mechanism, FDA status, trial evidence, boxed-warning safety, April 2026 list pricing, and the FTO, GLP1R, MC4R, and TCF7L2 variants that shape baseline GLP-1 biology.

Semaglutide and Tirzepatide are widely compared GLP-1 pathway compounds. This head-to-head covers mechanism, FDA status, trial evidence, boxed-warning safety, April 2026 list pricing, and the FTO, GLP1R, MC4R, and TCF7L2 variants that shape baseline GLP-1 biology.

Wegovy (semaglutide) and Zepbound (tirzepatide) are widely compared GLP-1 pathway compounds. This head-to-head covers mechanism, FDA status, trial evidence, boxed-warning safety, April 2026 list pricing, and the FTO, GLP1R, MC4R, and TCF7L2 variants that shape baseline GLP-1 biology.

Tirzepatide and Retatrutide are widely compared GLP-1 pathway compounds. This head-to-head covers mechanism, FDA status, trial evidence, boxed-warning safety, April 2026 list pricing, and the FTO, GLP1R, MC4R, and TCF7L2 variants that shape baseline GLP-1 biology.

Wegovy (semaglutide) and Zepbound (tirzepatide) are widely compared GLP-1 pathway compounds. This head-to-head covers mechanism, FDA status, trial evidence, boxed-warning safety, April 2026 list pricing, and the FTO, GLP1R, MC4R, and TCF7L2 variants that shape baseline GLP-1 biology.

Trulicity (dulaglutide, Eli Lilly) and Ozempic (semaglutide, Novo Nordisk) are once-weekly GLP-1 receptor agonists FDA-approved for type 2 diabetes. This head-to-head covers mechanism, SUSTAIN 7 data, boxed-warning safety, April 2026 list pricing, and the FTO, GLP1R, and MC4R variants that shape every GLP-1 response.

GLP-1 receptor agonist medications (GLP-1 receptor agonists) and tirzepatide are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Rybelsus (oral semaglutide) and Ozempic (semaglutide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including FTO, GLP1R, and MC4R — that apply regardless of which compound is prescribed.

Ozempic (semaglutide) and Zepbound (tirzepatide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.